Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.

Ingela Franck LissbrantEugenio VentimigliaDavid RobinsonMagnus TörnblomMarie Hjälm-ErikssonMats LambeYasin FolkvaljonPär Stattin

Published in: Scandinavian journal of urology (2018)

Less than one-third of potentially eligible men with CRPC received NOVAs in 2015-2016. There were large differences in use according to age and region of residence, indicating that efforts are needed to improve equal access to novel cancer drugs.

Keyphrases

prostate cancer
papillary thyroid
middle aged
radical prostatectomy
squamous cell
squamous cell carcinoma
lymph node metastasis
childhood cancer